Doi.org/10.3324/haematol.2015.126672
Revision as of 05:40, 18 August 2022 by 187.21.138.9 (talk) (Created page with "== Target Article == Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib; Lipsky AH, Farooqui MZ, Tian X, et al.; Haematologica; 2015; https://doi.org/10.3324/haematol.2015.126672 == Article providing comments == Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib; Tam, C. S.; Kamel, S.; ;...")
Target Article[edit | edit source]
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib; Lipsky AH, Farooqui MZ, Tian X, et al.; Haematologica; 2015; https://doi.org/10.3324/haematol.2015.126672
Article providing comments[edit | edit source]
Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib; Tam, C. S.; Kamel, S.; ; Haematologica; 2016-3-1 https://doi.org/10.3324/haematol.2015.139030
Summary[edit | edit source]
Note: Opened to append information.